180 related articles for article (PubMed ID: 29077044)
1. Inhibition of Human Kallikrein 5 Protease by Triterpenoids from Natural Sources.
Matsubara Y; Matsumoto T; Koseki J; Kaneko A; Aiba S; Yamasaki K
Molecules; 2017 Oct; 22(11):. PubMed ID: 29077044
[TBL] [Abstract][Full Text] [Related]
2. Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel.
Coda AB; Hata T; Miller J; Audish D; Kotol P; Two A; Shafiq F; Yamasaki K; Harper JC; Del Rosso JQ; Gallo RL
J Am Acad Dermatol; 2013 Oct; 69(4):570-7. PubMed ID: 23871720
[TBL] [Abstract][Full Text] [Related]
3. Light-emitting diodes downregulate cathelicidin, kallikrein and toll-like receptor 2 expressions in keratinocytes and rosacea-like mouse skin.
Lee JB; Bae SH; Moon KR; Na EY; Yun SJ; Lee SC
Exp Dermatol; 2016 Dec; 25(12):956-961. PubMed ID: 27315464
[TBL] [Abstract][Full Text] [Related]
4.
Roh KB; Ryu DH; Cho E; Weon JB; Park D; Kweon DH; Jung E
Molecules; 2020 Nov; 25(23):. PubMed ID: 33256158
[TBL] [Abstract][Full Text] [Related]
5. Identification of lympho-epithelial Kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor.
Meyer-Hoffert U; Wu Z; Schröder JM
PLoS One; 2009; 4(2):e4372. PubMed ID: 19190773
[TBL] [Abstract][Full Text] [Related]
6. Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin.
Kanada KN; Nakatsuji T; Gallo RL
J Invest Dermatol; 2012 May; 132(5):1435-42. PubMed ID: 22336948
[TBL] [Abstract][Full Text] [Related]
7. Persistent kallikrein 5 activation induces atopic dermatitis-like skin architecture independent of PAR2 activity.
Zhu Y; Underwood J; Macmillan D; Shariff L; O'Shaughnessy R; Harper JI; Pickard C; Friedmann PS; Healy E; Di WL
J Allergy Clin Immunol; 2017 Nov; 140(5):1310-1322.e5. PubMed ID: 28238749
[TBL] [Abstract][Full Text] [Related]
8. Kallikrein-related peptidase-8 (KLK8) is an active serine protease in human epidermis and sweat and is involved in a skin barrier proteolytic cascade.
Eissa A; Amodeo V; Smith CR; Diamandis EP
J Biol Chem; 2011 Jan; 286(1):687-706. PubMed ID: 20940292
[TBL] [Abstract][Full Text] [Related]
9. Kallikrein-related peptidase 5 functions in proteolytic processing of profilaggrin in cultured human keratinocytes.
Sakabe J; Yamamoto M; Hirakawa S; Motoyama A; Ohta I; Tatsuno K; Ito T; Kabashima K; Hibino T; Tokura Y
J Biol Chem; 2013 Jun; 288(24):17179-89. PubMed ID: 23629652
[TBL] [Abstract][Full Text] [Related]
10. Chlorogenic Acid Isomers Isolated from
Roh KB; Jang Y; Cho E; Park D; Kweon DH; Jung E
Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203672
[TBL] [Abstract][Full Text] [Related]
11. Kallikrein expression and cathelicidin processing are independently controlled in keratinocytes by calcium, vitamin D(3), and retinoic acid.
Morizane S; Yamasaki K; Kabigting FD; Gallo RL
J Invest Dermatol; 2010 May; 130(5):1297-306. PubMed ID: 20090765
[TBL] [Abstract][Full Text] [Related]
12. STAT3 maintains skin barrier integrity by modulating SPINK5 and KLK5 expression in keratinocytes.
Kim J; Kim MG; Jeong SH; Kim HJ; Son SW
Exp Dermatol; 2022 Feb; 31(2):223-232. PubMed ID: 34378233
[TBL] [Abstract][Full Text] [Related]
13. Screening of chemical libraries in pursuit of kallikrein-5 specific inhibitors for the treatment of inflammatory dermatoses.
Di Paolo CT; Filippou PS; Yu Y; Poda G; Diamandis EP; Prassas I
Clin Chem Lab Med; 2019 Oct; 57(11):1737-1743. PubMed ID: 31129650
[TBL] [Abstract][Full Text] [Related]
14. Topical Treatment of Rosacea with Ivermectin Inhibits Gene Expression of Cathelicidin Innate Immune Mediators, LL-37 and KLK5, in Reconstructed and Ex Vivo Skin Models.
Thibaut de Ménonville S; Rosignoli C; Soares E; Roquet M; Bertino B; Chappuis JP; Defoin-Platel/Chaussade C; Piwnica D
Dermatol Ther (Heidelb); 2017 Jun; 7(2):213-225. PubMed ID: 28243927
[TBL] [Abstract][Full Text] [Related]
15. A Potent and Selective Kallikrein-5 Inhibitor Delivers High Pharmacological Activity in Skin from Patients with Netherton Syndrome.
Liddle J; Beneton V; Benson M; Bingham R; Bouillot A; Boullay AB; Brook E; Cryan J; Denis A; Edgar E; Ferrie A; Fouchet MH; Grillot D; Holmes DS; Howes A; Krysa G; Laroze A; Lennon M; McClure F; Moquette A; Nicodeme E; Santiago B; Santos L; Smith KJ; Thorpe JH; Thripp G; Trottet L; Walker AL; Ward SA; Wang Y; Wilson S; Pearce AC; Hovnanian A
J Invest Dermatol; 2021 Sep; 141(9):2272-2279. PubMed ID: 33744298
[TBL] [Abstract][Full Text] [Related]
16. Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome.
Furio L; de Veer S; Jaillet M; Briot A; Robin A; Deraison C; Hovnanian A
J Exp Med; 2014 Mar; 211(3):499-513. PubMed ID: 24534191
[TBL] [Abstract][Full Text] [Related]
17. SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7.
Wang S; Olt S; Schoefmann N; Stuetz A; Winiski A; Wolff-Winiski B
Exp Dermatol; 2014 Jul; 23(7):524-6. PubMed ID: 24848304
[TBL] [Abstract][Full Text] [Related]
18. Selective Substrates and Inhibitors for Kallikrein-Related Peptidase 7 (KLK7) Shed Light on KLK Proteolytic Activity in the Stratum Corneum.
de Veer SJ; Furio L; Swedberg JE; Munro CA; Brattsand M; Clements JA; Hovnanian A; Harris JM
J Invest Dermatol; 2017 Feb; 137(2):430-439. PubMed ID: 27697464
[TBL] [Abstract][Full Text] [Related]
19. Exonic mutations associated with atopic dermatitis disrupt lympho-epithelial Kazal-type related inhibitor action and enhance its degradation.
Ramesh K; Matta SA; Chew FT; Mok YK
Allergy; 2020 Feb; 75(2):403-411. PubMed ID: 31407378
[TBL] [Abstract][Full Text] [Related]
20. Exploring the active site binding specificity of kallikrein-related peptidase 5 (KLK5) guides the design of new peptide substrates and inhibitors.
de Veer SJ; Swedberg JE; Brattsand M; Clements JA; Harris JM
Biol Chem; 2016 Dec; 397(12):1237-1249. PubMed ID: 26894578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
